AI-driven target discovery platform for neurotherapeutics that predicts drug candidate potential across multiple neural disorders simultaneously.
Exin Therapeutics is building a multimodal AI platform for discovering neurotherapeutics that target neural circuits across neurological disorders. The platform predicts a drug candidate's potential on multiple neural disorders simultaneously, is agnostic to therapeutic modality, and is independent of genetic background. The company focuses initially on epilepsies associated with autism and Parkinson's disease, with the potential to expand to any neurological disorder involving dysfunction in neural activity. Exin Therapeutics is a product of Exin Therapeutics.